Zoetis down -50% over the past year

=== SUMMARY === - Post highlights Zoetis (ZTS), the world’s leading animal health company, which has declined ~50% in the past year. - Author’s thesis: at 13x P/E with ~9% EPS growth, the stock offers a compelling value opportunity. - Quality assessment: Short but data-backed thesis; not a deep dive but a clear value call – leans toward well-reasoned speculation. === SENTIMENT === BULLISH === TRADE IDEAS === ZTS - LONG | confidence: 0.75 | sentiment: +0.70 Speaker: u/investorinvestor Thesis: 1. THE FACT: ZTS trades at 13x P/E with consistent 9% EPS growth, a rare combo in a high-quality, defensive subsector. 2. THE BRIDGE: A 50% drawdown has compressed valuation to levels not seen in years, creating a margin of safety for mean reversion. 3. THE VERDICT: Buy a dominant animal pharma franchise at a cheap multiple with steady growth – classic value play. 4. RISKS: Slowing pet adoption/post-pandemic demand normalization, generic competition, regulatory changes in veterinary drugs, or negative currency effects. Timeframe: medium-term (12-24 months) Key Points: - 50% drop created deep value entry - 13x PE with 9% growth is attractive - Leading market position in animal health - Defensive secular growth story - Potential catalyst: mean reversion or M&A